Dr. Andras Fiser


"Our scientific team’s mission at Einstein-Montefiore is to rapidly develop a detection and treatment approach for drug resistant bacterial infections. We will accomplish this through technological development using a highly translational approach, which does not fit traditional funding opportunities. Being a recipient of the XSeed Award has allowed us to be highly innovative to employ non-canonical perspectives to combat drug resistance in infectious diseases and provide a breakthrough technology to improve care."

Creating a stronger, more equitable New York by bridging promising translational research to marketplace and commercial success
The X-Seed Award was created by Deerfield as a result of the partnership announced in September 2019 between NYCEDC and Deerfield to develop the Cure life sciences campus, which opened in January 2021. The 12-story vertical campus is bringing together innovators from academia, government, industry, and the not-for-profit sectors under one roof to advance human health and accelerate the fight against disease.

Deerfield is a healthcare investment management firm committed to advancing healthcare through investment, information and philanthropy. For more information, please visit www.deerfield.com.

Leadership

James Flynn
Claire Pomeroy
Nancy Thornberry
Elise Wang
Joseph Pearlberg

News

Deerfield Management Announces XSeed Award Winners
Second Annual $500,000 XSeed Award Launched by Deerfield Management to Support Underfunded and Underrepresented NYC Life Science Startups
ARCHIVES
On April 20th 2021, the XSeed Winners were announced at “Deerfield Live at the Cure”.
Read More
Deerfield Launches a Novel Funding Mechanism, the X-Seed Award, to Support Early-Stage Life Sciences and Underrepresented Company Founders
Read More
Deerfield Management Announces Winners of the First Annual XSeed Award
Read More

Proposal Submission

2021-2022 Key Research Focus – Neurodegeneration
Currently Closed

Despite significant investment in the area of neurodegeneration, our understanding of the pathogenesis of neurodegenerative diseases remains limited and our ability to bring new therapeutics to patients is lacking. At the same time, novel technological advances such as those in genetics, proteomics, imaging, single cell sequencing, and epitranscriptomics, stem cell biology, and organoids, have afforded new approaches to understanding the complex nature of neurodegenerative diseases, including the interplay of different cell types, the ability to monitor surrogate markers of disease progression, genetic modifiers of disease phenotype, and the ability to parse the differences among neurodegenerative diseases with overlapping clinical features.

The purpose of this RFA is to solicit proposals that provide novel approaches that address key questions regarding the pathogenesis, progression, diagnosis, or treatment of neurodegenerative diseases. This RFA anticipates that successful proposals will describe work that lies on the continuum of basic science and translational medicine. Neurodegenerative diseases that affect either the central or peripheral nervous system are in scope, including, but not limited to: Alzheimer’s disease, Lewy Body Dementia, Frontotemporal Dementia, tauopathies in general, Huntington’s Disease, Amyotrophic Lateral Sclerosis, Spinocerebellar Atrophy, and Parkinson’s Disease.

Examples of areas of research that will be considered include, but are not limited to:

  • Development of novel cellular and animal models, such as iPSCs and brain organoids that recapitulate the relevant pathophysiological pathways for study of neurodegeneration
  • Novel biomarker approaches, including biochemical and imaging biomarkers, for patient selection strategies or monitoring the course of disease
  • Identification of novel chemical matter or biologics for therapeutic intervention for known cellular targets that are implicated in neurodegeneration
  • Identification of novel targets with supporting genetic validation
  • Approaches that establish causality of known variants or establish common pathways that disparate variants converge on
  • Approaches that modulate or explore mechanisms related to the immune system or inflammatory processes as a therapeutic approach

Beginning on November 1, applicants interested in the Xseed Grant Award will complete an online Letter of Intent along with a one-page non-confidential executive summary outlining the specific aims of the project.

The 2021-2022 submission cycle will close at 11:59 PM EST on January 7th, 2022.

All information provided in the proposal submission is non-confidential.

To view more details about the application and/or to submit a proposal please click here.

Contact

* is required field.

Error sending form, please try again.